Previous studies, analyzing the implications of CHEK2 P/LP variants for clinical care have utilized cohorts enriched for cases with metastatic PrCa [7], lethal PrCa [13,20], aggressive PrCa [10], early onset [6], or primarily analyzing ethnic-specific founder effects [21]. This evidence concerns the gene CHEK2 and pure red-cell aplasia.